Complement C5a Drug Development for Immuno-Dermatology Indications
Time: 1:45 pm
day: Day One Clinical Track PM
Details:
- The role of C5a/C5aR in chronic inflammation has become increasingly clear in recent years, making C5a & C5aR attractive targets for many immune-inflammatory diseases
- InflaRx have two potential therapeutics targeting C5a with the anti-C5a antibody (vilobelimab) and an oral anti-C5aR inhibitor (INF-904); with initial focus on immune-dermatology indications such as hidradenitis suppurativa, pyoderma gangrenosum and chronic spontaneous urticaria
